In vitro and in vivo activities of sparfloxacin in Legionella infections.
Saito
A
A
First Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan.
Gaja
M
M
D000328:Adult; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D004917:Erythromycin / Q000494:pharmacology; D024841:Fluoroquinolones; D006168:Guinea Pigs; D006801:Humans; D066298:In Vitro Techniques; D016952:Legionella pneumophila / Q000187:drug effects*; D007877:Legionnaires' Disease / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D008826:Microbial Sensitivity Tests; D009504:Neutrophils / Q000187:drug effects / Q000382:microbiology; D015363:Quinolones / Q000494:pharmacology*; D013534:Survival
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D004917:Erythromycin; C061363:sparfloxacin